Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents

International Journal of Hematology

Volumn 99, Issue 4, 2014, Pages 441-449

  Kuroda, Junya ^a   Shimura, Yuji ^a   Ohta, Kensuke ^b   Tanaka, Hirokazu ^c   Shibayama, Hirohiko ^d   Kosugi, Satoru ^e   Fuchida, Shinichi ^f   Kobayashi, Masayuki ^g   Kaneko, Hitomi ^h   Uoshima, Nobuhiko ⁱ   Ishii, Kazuyoshi ^j   Nomura, Shosaku ^j   Taniwaki, Masafumi ^a   Takaori Kondo, Akifumi ^g   Shimazaki, Chihiro ^f   Tsudo, Mitsuru ^h   Hino, Masayuki ^k   Matsumura, Itaru ^c   Kanakura, Yuzuru ^d  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SAISEIKAI NAKATSU HOSPITAL   (Japan)

^c KINKI UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^f Department of Hematology Social Insurance Kyoto Hospital ^*  (Japan)

^g KYOTO UNIVERSITY   (Japan)

^h OSAKA RED CROSS HOSPITAL   (Japan)

ⁱ MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^j KANSAI MEDICAL UNIVERSITY   (Japan)

^k OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

International staging system; Melphalan; Multiple myeloma; Novel agent; Prednisolone

Indexed keywords

BORTEZOMIB; CALCIUM; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL STAGING SYSTEM; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL PREDICTION; SURVIVAL TIME; TIME TO TREATMENT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; MIDDLE AGED; MORTALITY; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDNISOLONE; PROGNOSIS; PYRAZINES; RETREATMENT; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84899630064     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1539-5     Document Type: Article

References (40)

1. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV. San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121:884-92.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
3. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281-90. (Pubitemid 350106321)
4. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013;27:2351-6.
5. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22:3269-76. (Pubitemid 41103682)
6. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055-66.
7. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953-9.
8. Kuroda J, Nagoshi H, Shimura Y, Taniwaki M. Elotuzumab and Daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther. 2013;28:368-73.
9. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood. 1968;31:1-10.
10. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep. 1962;21:87-99.
11. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-18. (Pubitemid 47516593)
12. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009;113:3435-42.
13. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116:1405-12.
14. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28:3160-6.
15. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231-8.
16. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-31. (Pubitemid 43363369)
17. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-17.
18. Hernández JM, García-Sanz R, Golvano E, Bladé J, Fernandez-Calvo J, Trujillo J, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127:159-64. (Pubitemid 39371808)
19. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259-66.
20. Medical Research Council's Working Party on Leukaemia in. Adults. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults. Br J Cancer. 1980;42:823-30.
21. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16:3832-42.
22. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-20.
23. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73. (Pubitemid 44264086)
24. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239-47.
25. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25:689-96.
26. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int J Hematol. 2013;97:333-44.
27. Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, et al. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leuk Res. 2013;37:1070-6.
28. Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, et al. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematol Oncol. 2013;31:356-62.
29. Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wäsch R, et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013;13:541-51.
30. Zhuang J, Da Y, Li H, Han B, Wan X, Zhu T, et al. Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leuk Res. 2014;38:188-93.
31. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011;94:310-20.
32. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025-31.
33. Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115:4168-73.
34. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009;23:1941-56.
35. Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013;162:348-59.
36. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148.
37. Caldarella C, Isgrò MA, Treglia I, Treglia G. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma? Int J Hematol. 2012;96:685-91.
38. Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, et al. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol. 2012;95:516-26.
39. Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wäsch R, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1:e35.
40. Bataille R, Annweiler C, Beauchet O. Multiple myeloma international staging system: "staging" or simply "aging" system? Clin Lymphoma Myeloma Leuk. 2013;13:635-7.